Paid Clinical Trials in Stony Brook, NY

As of June 2026, 202 paid clinical trials are recruiting in Stony Brook, New York. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 26, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

202 clinical trials

↓ Download CSV

The VENTOR Clinical Study

for Cardiac Arrest (CA)

1 location in Stony Brook

Sponsor: CoLabs Medical

Sex: All·Age: 18 - 75

Code: NCT06759389·Recruiting

Apply to this trial

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

for Relapsed or Refractory Multiple Myeloma (RRMM)

22 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06615479·Phase 3·Recruiting

Apply to this trial

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

for Acute Kidney Injury

50 locations incl. Birmingham

Sponsor: Indiana University

Sex: All·Age: 0 Minutes - 2 Weeks

Code: NCT06823115·Enrolling By Invitation

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

for Hidradenitis Suppurativa (HS)

Drug: Povorcitinib

108 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT06855498·Phase 3·Recruiting

Apply to this trial

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

190 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting

Apply to this trial

Opioid Sparing Effect of an ISP Nerve Block on Post-Op Pain Control in Posterior Cervical Spine Surgery

for Pain, Postoperative

1 location in Stony Brook

Sponsor: Stony Brook University

Sex: All·Age: 18 - 75·Accepts healthy volunteers

Code: NCT06570577·Recruiting

Apply to this trial

Raman Spectroscopy and Skin Cancer

for Skin Cancer

1 location in Stony Brook

Sponsor: Tiezhi Zhang

Sex: All·Age: 18+

Code: NCT06384924·Recruiting

Apply to this trial

StrokeNet Thrombectomy Endovascular Platform

for Ischemic Stroke

41 locations incl. Birmingham

Sponsor: Medical University of South Carolina

Sex: All·Age: 18+

Code: NCT06289985·Recruiting

Apply to this trial

Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

for Postpartum Hemorrhage

1 location in Stony Brook

Sponsor: Stony Brook University

Sex: Female·Age: 18+·Accepts healthy volunteers

Code: NCT05245227·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

for Chronic Graft-versus-host-disease

33 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 12+

Code: NCT06585774·Phase 3·Recruiting

Apply to this trial

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

for Non-small Cell Lung Cancer

36 locations incl. Anchorage

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT06712316·Phase 2, Phase 3·Recruiting

Apply to this trial

Testing a Brief Motivational Intervention to Increase Physical Activity for Cancer Survivors

for Cancer

1 location in Stony Brook

Sponsor: Stony Brook University

Sex: All·Age: All ages

Code: NCT07215091·Recruiting

Apply to this trial

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

for Multiple Myeloma

Drug: Belantamab mafodotin

30 locations incl. Mobile

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT06679101·Phase 3·Recruiting

Apply to this trial

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

for Anatomic Stage IV Breast Cancer AJCC v8

262 locations incl. Tucson

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06500455·Phase 3·Recruiting

Apply to this trial

CoMind Early Feasibility Study

for Intracranial Pressure

14 locations incl. Sacramento

Sponsor: CoMind Technologies Limited

Sex: All·Age: 18+

Code: NCT06368648·Recruiting

Apply to this trial

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

for Systemic Sclerosis

15 locations incl. Orange

Sponsor: Nkarta, Inc.

Sex: All·Age: 18 - 75

Code: NCT06733935·Phase 1, Phase 2·Recruiting

Apply to this trial

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

for Major Depressive Disorder (MDD)

1 location in Stony Brook

Sponsor: Stony Brook University

Sex: All·Age: 18 - 65·Accepts healthy volunteers

Code: NCT07095205·Phase 4·Recruiting

Apply to this trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

221 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06317649·Phase 2·Recruiting

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

165 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting

Apply to this trial

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

211 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting

Apply to this trial

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

for Monoclonal Gammopathy of Undetermined Significance (MGUS)

Drug: Linvoseltamab

7 locations incl. Baltimore

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06140524·Phase 2·Recruiting

Apply to this trial

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

167 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting

Apply to this trial

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

for Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)

6 locations incl. Los Angeles

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06535607·Phase 2·Recruiting

Apply to this trial

Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)

for Tricuspid Regurgitation

9 locations incl. Thousand Oaks

Sponsor: Innoventric LTD

Sex: All·Age: 18 - 85

Code: NCT06212193·Recruiting

Apply to this trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

for Advanced Breast Cancer

Drug: Camizestrant

54 locations incl. Gilbert

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06380751·Phase 3·Recruiting

Apply to this trial

Long-term Safety and Tolerability of BHV-7000

for Focal Epilepsy

115 locations incl. Birmingham

Sponsor: Biohaven Therapeutics Ltd.

Sex: All·Age: 18 - 75

Code: NCT06443463·Phase 2·Enrolling By Invitation

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

for Advanced Lung Non-Small Cell Carcinoma

319 locations incl. Fayetteville

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 70+

Code: NCT06096844·Phase 3·Recruiting

Apply to this trial

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

for Advanced Melanoma

Drug: Nivolumab

50 locations incl. Gilbert

Sponsor: Replimune, Inc.

Sex: All·Age: 12+

Code: NCT06264180·Phase 3·Recruiting

Apply to this trial

Global Paradise System US Post Approval Study

for Hypertension

39 locations incl. Sacramento

Sponsor: ReCor Medical, Inc.

Sex: All·Age: 18+

Code: NCT06297291·Recruiting

Apply to this trial

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

for Cardiovascular Risk

Drug: Ziltivekimab

208 locations incl. Alexander City

Sponsor: Novo Nordisk A/S

Sex: All·Age: 18+

Code: NCT06118281·Phase 3·Recruiting

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

335 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting

Apply to this trial

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

for Lupus Nephritis

17 locations incl. Little Rock

Sponsor: Nkarta, Inc.

Sex: All·Age: 18 - 75

Code: NCT06557265·Phase 1, Phase 2·Recruiting

Apply to this trial

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

for Breast Cancer

53 locations incl. Anchorage

Sponsor: Exact Sciences Corporation

Sex: All·Age: 18+

Code: NCT06401421·Recruiting

Apply to this trial

Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)

for Acute Myeloid Leukemia

1 location in Stony Brook

Sponsor: Suhu Liu

Sex: All·Age: 18+

Code: NCT06297551·Recruiting

Apply to this trial

The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).

for Intracranial Aneurysm

22 locations incl. Englewood

Sponsor: Medtronic Neurovascular Clinical Affairs

Sex: All·Age: 18 - 75

Code: NCT02998229·Recruiting

Apply to this trial

IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

for Type B Aortic Dissection

61 locations incl. Birmingham

Sponsor: Duke University

Sex: All·Age: 21+

Code: NCT06087029·Recruiting

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

46 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting

Apply to this trial

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

for Heart Failure and Impaired Kidney Function

Drug: Dapagliflozin

166 locations incl. Alexander City

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06307652·Phase 3·Recruiting

Apply to this trial

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for Non-Small Cell Lung Cancer

Drug: Rilvegostomig

63 locations incl. Anchorage

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06357533·Phase 3·Recruiting

Apply to this trial

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for Non-Small Cell Lung Cancer

Drug: Livmoniplimab

19 locations incl. La Jolla

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06236438·Phase 2, Phase 3·Recruiting

Apply to this trial